Anti-Noxa antibody [114C307]

• WB

Unknown

Western blot - Anti-Noxa antibody [114C307] (AB13654)

Western blot detection of Noxa in RL-7 cell (a follicular lymphoma) lysate. A protein of approximate molecular weight of 11 kDa is detected using ab13654 at 2 μg/ml.

Western blot detection of Noxa in RL-7 cell (a follicular lymphoma) lysate. A protein of approximate molecular weight of 11 kDa is detected using ab13654 at 2 µg/ml.

All lanes:

Western blot - Anti-Noxa antibody [114C307] (ab13654)

Predicted band size: 6 kDa

false

• IHC-P

Supplier Data

Immunohistochemistry paraffin embedded sections - Anti-Noxa antibody [114C307] (AB13654)

Bouin-fixed, paraffin-embedded human tonsil tissue stained for Chronic Lymphocytic Leukemia (CLL) xenograft tissue stained for Noxa using ab13654 at 1/2000 dilution in immunohistochemical analysis.

• Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-Noxa antibody [114C307] (AB13654)

Overlay histogram showing Jurkat cells stained with ab13654 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab13654, 1μg/1x10⁶ cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1](ab91353, 2μg/1x10⁶ cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in Jurkat cells fixed with 80% methanol/permeabilized in 0.1% PBS-Tween used under the same conditions.

• WB

CiteAb

Western blot - Anti-Noxa antibody [114C307] (AB13654)

Western Blotting using Anti-Noxa antibody [114C307], ab13654. Publication image from Portelinha, A. et al., 2023, Nat Commun, 36934096. Legend direct from paper.

The BCL-2 inhibitor venetoclax synergizes with PLK4 inhibition and eliminates polyploid cells.a Heatmap representing the percentage of cell viability values for the CFI-resistant cell lines in response to CFI and venetoclax combined treatment for 72 h, as assessed by CellTiter-Glo assay. Cell viability values are represented in a heatmap colored from red (0% inhibition) or blue to white (50–100% inhibition). Values represent the average of three independent dose-titration curves (n = 3). b Representative confocal c quantification of OCI-Ly19 cells treated with CFI (25 nM), Venetoclax (25 nM), or a combination of both treatments for 72 h treatment. Cells were fixed and stained for pericentrin. Insets are 4X magnified. Scale bar, 3 µm. A minimum of three z-stack images were captured under the same condition. d Representative cell cycle analysis after PI staining of HBL-1, Daudi, and SU-DHL-6 cell lines after 72 h treatment of CFI (50 nM), venetoclax (50 nM), or combination (50 nM of each drug). e Quantification of cells at different stages of the cell cycle shows CFI-generated polyploid cells are eliminated in cell lines with high synergy between CFI and venetoclax. Data were presented as mean ± SD, n = 3. f Representative DNA histograms for cell cycle analysis of HBL-1 after 72 h treatment of Dihydrocytochalasin B (DCB) (1.5 µM), venetoclax (50 nM), or combination of both drugs. g Stacked bar graph showing the percentage of cells at various stages of the cell cycle in HBL-1 treated with DCB or venetoclax alone or with a combination of both drugs. Data were presented as mean ± SD, n = 2. h Western blot analysis of BCL-2 family proteins levels 72 h following combinational treatment with indicated drugs. Representative western blots from one of three experiments performed.α-tubulin is shown to indicate equivalence of loading. Ven Venetoclax, Combo combination of CFI and Venetoclax. Source data for panels a, c, e, g, h are provided as a Source Data file.

false